Inactivation of neuronal forebrain A2A receptors protects dopaminergic neurons in a mouse model of Parkinson’s disease
Open Access
- 20 November 2009
- journal article
- Published by Wiley in Journal of Neurochemistry
- Vol. 111 (6), 1478-1489
- https://doi.org/10.1111/j.1471-4159.2009.06425.x
Abstract
Adenosine A2A receptors antagonists produce neuroprotective effects in animal models of Parkinson’s disease (PD). As neuroinflammation is involved in PD pathogenesis, both neuronal and glial A2A receptors might participate to neuroprotection. We employed complementary pharmacologic and genetic approaches to A2A receptor inactivation, in a multiple MPTP mouse model of PD, to investigate the cellular basis of neuroprotection by A2A antagonism. MPTP·HCl (20 mg/kg daily for 4 days) was administered in mice treated with the A2A antagonist SCH58261, or in conditional knockout mice lacking A2A receptors on forebrain neurons (fbnA2AKO mice). MPTP-induced partial loss of dopamine neurons in substantia nigra pars compacta (SNc) and striatum (Str), associated with increased astroglial and microglial immunoreactivity in these areas. Astroglia was similarly activated 1, 3, and 7 days after MPTP administration, whereas maximal microglial reactivity was detected on day 1, returning to baseline 7 days after MPTP administration. SCH58261 attenuated dopamine cell loss and gliosis in SNc and Str. Selective depletion of A2A receptors in fbnA2AKO mice completely prevented MPTP-induced dopamine neuron degeneration and gliosis in SNc, and partially counteracted gliosis in Str. Results provide evidence of a primary role played by neuronal A2A receptors in neuroprotective effects of A2A antagonists in a multiple MPTP injections model of PD. With the symptomatic antiparkinsonian potential of several A2A receptor antagonists being pursued in clinical trials, this study adds to the rationale for broader clinical benefit and use of these drugs early in the treatment of PD.Keywords
This publication has 58 references indexed in Scilit:
- GDNF control of the glutamatergic cortico‐striatal pathway requires tonic activation of adenosine A2A receptorsJournal of Neurochemistry, 2009
- Adenosine A2A receptor antagonists exert motor and neuroprotective effects by distinct cellular mechanismsAnnals of Neurology, 2008
- Blockade of adenosine A2A receptors prevents staurosporine-induced apoptosis of rat hippocampal neuronsNeurobiology of Disease, 2007
- Adenosine A2A receptors and basal ganglia physiologyProgress in Neurobiology, 2007
- Survival of midbrain dopaminergic cells after lesion or deep brain stimulation of the subthalamic nucleus in MPTP-treated monkeysBrain, 2007
- Adenosine A2AReceptors in Bone Marrow-Derived Cells But Not in Forebrain Neurons Are Important Contributors to 3-Nitropropionic Acid-Induced Striatal Damage as Revealed by Cell-Type-Selective InactivationJournal of Neuroscience, 2006
- Adenosine A2A receptor stimulation potentiates nitric oxide release by activated microgliaJournal of Neurochemistry, 2005
- Adenosine and glutamate extracellular concentrations and mitogen-activated protein kinases in the striatum of Huntington transgenic mice. Selective antagonism of adenosine A2A receptors reduces transmitter outflowNeurobiology of Disease, 2004
- Endogenous Activation of mGlu5 Metabotropic Glutamate Receptors Contributes to the Development of Nigro-Striatal Damage Induced by 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine in MiceJournal of Neuroscience, 2004
- Neurochemical findings in the MPTP model of Parkinson's diseaseJournal of Neural Transmission, 2001